secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001104659-25-074163
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q2 net income $59.6M, revenue $101.7M; raises FY2025 guidance to $270-280M
--------------------------------------------------------------------------------

- Q2 2025 total revenue $101.7M (net product sales $58.9M, up 76% YoY); net income $59.6M vs loss $1.0M in Q2 2024.
- Raised FY2025 guidance: total revenue $270-280M (prev $200-210M); net product sales $210-220M (prev $185-192M).
- Cash and investments increased to $108.4M from $77.3M at Dec 31, 2024.
- TAVALISSE sales $40.1M (+52% YoY), GAVRETO $11.8M, REZLIDHIA $7.0M (+36%).
- Completed enrollment in dose escalation part of Phase 1b study for R289 in R/R lower-risk MDS; dose expansion later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925074163/0001104659-25-074163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465925074163/tm2522417d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-074163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer